Pharmbio Korea will exclusively sell Clipper (beclomethasone dipropionate), an original ulcerative colitis treatment from Italian pharmaceutical company Chiesi, in Korea.

Clipper is a steroidal ulcerative colitis treatment, a long-acting extended-release tablet that provides the anti-inflammatory benefits of conventional oral steroids without the systemic side effects, Pharmbio Korea said on Wednesday.

Clipper's small tablet size improves adherence and once-daily dosing for patient convenience. In addition, a study showed that the combination of 5-ASA (mesalazine) and Clipper improved remission induction by 25 percent in patients with ulcerative colitis compared to 5-ASA alone, the company said.

"Clipper is an excellent product with clear advantages," Pharmbio Korea Chairman Nam Bong-kil said. "We expect to see synergies with our existing products. It will greatly benefit many people with ulcerative colitis."